Switching to Biosimilar Does Not Affect Clinical Remission in IBD Patients

Health News

Switching to Biosimilar Does Not Affect Clinical Remission in IBD Patients
BiosimilarIBDClinical Remission
  • 📰 Medscape
  • ⏱ Reading Time:
  • 7 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 55%

A systematic review found that switching from an originator product to a biosimilar did not significantly change the proportion of IBD patients in clinical remission. Other outcomes were similar between biosimilar and originator therapy. The results differ from a previous study and the Canadian Association of Gastroenterology and Crohn's recommended limiting biosimilar induction to previously untreated patients.

In a systematic review of real-world observational studies , it was found that the proportion of patients with IBD in clinical remission did not change significantly after switching from an originator product to a biosimilar. Other outcomes, such as loss of response and treatment cessation, were similar between patients who switched to a biosimilar and those who continued the originator therapy . The results differ from a previous study published in 2019.

The Canadian Association of Gastroenterology and Crohn's recommended limiting biosimilar induction to previously untreated patients

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Biosimilar IBD Clinical Remission Originator Therapy Observational Studies

 

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

3 ways the Credit Card Competition Act could affect consumers3 ways the Credit Card Competition Act could affect consumersIt won’t change how you use your credit cards to make purchases, but experts speculate that rewards would be different, and there could be security issues.
Read more »

Semaglutide Drug Shows Potential in Reducing Heart Disease RiskSemaglutide Drug Shows Potential in Reducing Heart Disease RiskA study presented at the American Heart Association meeting reveals that the drug semaglutide, used for weight management, can also reduce the risk of dying from heart disease in certain patients.
Read more »

Organized Retail Crime Still a Concern for InvestorsOrganized Retail Crime Still a Concern for InvestorsInvestors are keeping a close eye on retail earnings to see if organized retail crime continues to affect the sector.
Read more »

The Impact of Interest Rates on StocksThe Impact of Interest Rates on StocksThis article discusses the relationship between interest rates and stocks, and how changes in interest rates can affect borrowing, saving, spending, and investing.
Read more »



Render Time: 2026-04-01 17:57:38